A 14-month-old girl is referred to pediatric neurology for refractory epilepsy. She experienced her first seizure at 6 months of age—a prolonged hemiclonic seizure triggered by fever following routine vaccination. Since then, she has had recurrent prolonged seizures triggered by fever, hot baths, photic stimulation, and minor temperature elevations. Her EEG now shows the pattern marked **A** in the diagram: generalized polyspike-and-wave discharges at 3–4 Hz with a striking photoparoxysmal response to intermittent photic stimulation. Genetic testing reveals a heterozygous loss-of-function mutation in SCN1A. Which of the following best explains why sodium channel blockers (carbamazepine, oxcarbazepine, phenytoin) are contraindicated in this patient?

Question

Accepted Answer

D. SCN1A mutations impair inhibitory GABAergic interneurons, and sodium channel blockers further reduce inhibitory tone, paradoxically worsening seizures. ## Why "SCN1A mutations impair inhibitory GABAergic interneurons, and sodium channel blockers further reduce inhibitory tone, paradoxically worsening seizures" is right

Dravet syndrome is a channelopathy caused by loss-of-function mutations in SCN1A, which encodes the alpha-1 subunit of the voltage-gated sodium channel NaV1.1. Critically, NaV1.1 is preferentially expressed in inhibitory GABAergic interneurons. Loss of function in these interneurons reduces inhibitory tone in the cortex, lowering the seizure threshold and causing the characteristic generalized polyspike-and-wave pattern seen on EEG (marked **A**). Sodium channel blockers (carbamazepine, oxcarbazepine, phenytoin, lamotrigine) further suppress sodium influx in these already-compromised inhibitory neurons, paradoxically worsening seizures and precipitating status epilepticus. This is why these drugs are contraindicated in Dravet syndrome. First-line agents (valproate, clobazam, stiripentol) work through alternative mechanisms that do not further impair GABAergic inhibition. (Nelson Textbook of Pediatrics, 21st ed., Chapter 611: Dravet Syndrome)

## Why each distractor is wrong

- **SCN1A mutations cause loss of function in excitatory glutamatergic neurons...**: SCN1A is preferentially expressed in inhibitory interneurons, not excitatory neurons. The pathophysiology is loss of inhibition, not loss of excitation.
- **SCN1A mutations increase sodium influx into neurons...**: Loss-of-function mutations reduce sodium influx, not increase it. There is no "compensatory depolarization" needed; the problem is insufficient inhibitory drive.
- **SCN1A mutations affect the blood-brain barrier...**: SCN1A mutations are channelopathies affecting neuronal function, not blood-brain barrier transport. BBB integrity is not the primary mechanism.

**High-Yield:** Dravet syndrome = loss of function in inhibitory interneurons → sodium channel blockers worsen seizures by further reducing inhibition → use valproate, clobazam, stiripentol instead.

[cite: Nelson Textbook of Pediatrics, 21st ed., Chapter 611: Dravet Syndrome (SMEI)]

Answer

A. SCN1A mutations cause loss of function in excitatory glutamatergic neurons, and sodium channel blockers further reduce excitation needed for seizure control

Answer

B. SCN1A mutations affect the blood-brain barrier, and sodium channel blockers impair the active transport mechanisms needed to maintain seizure threshold

Answer

C. SCN1A mutations increase sodium influx into neurons, and sodium channel blockers prevent the necessary compensatory depolarization

Explanation

Why "SCN1A mutations impair inhibitory GABAergic interneurons, and sodium channel blockers further reduce inhibitory tone, paradoxically worsening seizures" is right

Why each distractor is wrong

Practice similar questions

Join our NEET PG community